CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability